Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Response to bortezomib and activation of osteoblasts in multiple myeloma.

Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G.

Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14. Review.

PMID:
17026821
2.

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.

Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G.

Br J Haematol. 2005 Oct;131(1):71-3.

PMID:
16173965
3.
4.

Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.

Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G.

Am J Hematol. 2007 Sep;82(9):831-3.

5.

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.

Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaissé JM.

Leuk Res. 2008 Nov;32(11):1661-8. doi: 10.1016/j.leukres.2008.02.019. Epub 2008 Apr 18.

PMID:
18394701
6.

Proteasome inhibitor therapy in multiple myeloma.

Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC.

Mol Cancer Ther. 2005 Apr;4(4):686-92. Review.

7.

Myeloma bone disease and proteasome inhibition therapies.

Terpos E, Sezer O, Croucher P, Dimopoulos MA.

Blood. 2007 Aug 15;110(4):1098-104. Epub 2007 May 9. Review.

8.

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.

Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G.

Haematologica. 2011 Feb;96(2):333-6. doi: 10.3324/haematol.2010.031302. Epub 2010 Oct 15.

9.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
10.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361
11.

Proteasome inhibition for treatment of multiple myeloma: clinical update.

Stadtmauer EA.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S10-5. Review.

PMID:
19795531
12.

Bortezomib and its role in the management of patients with multiple myeloma.

Orlowski RZ.

Expert Rev Anticancer Ther. 2004 Apr;4(2):171-9. Review.

PMID:
15056047
13.

Proteasome inhibition in multiple myeloma.

Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.

Eur J Cancer. 2006 Jul;42(11):1623-39. Epub 2006 Jul 3. Review.

PMID:
16820291
14.

Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.

Lee SE, Min CK, Yahng SA, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Park CW.

Eur J Haematol. 2011 Jan;86(1):83-6. doi: 10.1111/j.1600-0609.2010.01523.x. Epub 2010 Nov 11.

PMID:
20946110
15.

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.

Ludwig H, Khayat D, Giaccone G, Facon T.

Cancer. 2005 Nov 1;104(9):1794-807. Review.

16.

The proteasome: a novel target for anticancer therapy.

Montagut C, Rovira A, Albanell J.

Clin Transl Oncol. 2006 May;8(5):313-7. Review.

PMID:
16760005
17.

The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.

Eda H, Aoki K, Kato S, Okawa Y, Takada K, Tanaka T, Marumo K, Ohkawa K.

Eur J Haematol. 2010 Jul;85(1):68-75. doi: 10.1111/j.1600-0609.2010.01435.x. Epub 2010 Feb 23. Erratum in: Eur J Haematol. 2010 Oct;85(4):370.

PMID:
20192985
18.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.

N Engl J Med. 2003 Jun 26;348(26):2609-17.

19.

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.

Richardson PG, Mitsiades C, Ghobrial I, Anderson K.

Curr Opin Oncol. 2006 Nov;18(6):598-608. Review.

PMID:
16988581
20.

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Ozaki S, Tanaka O, Fujii S, Shigekiyo Y, Miki H, Choraku M, Kagawa K, Asano J, Takeuchi K, Kitazoe K, Hashimoto T, Abe M, Matsumoto T.

Int J Hematol. 2007 Aug;86(2):180-5.

PMID:
17875535

Supplemental Content

Support Center